SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-043959
Filing Date
2021-08-12
Accepted
2021-08-12 16:05:53
Documents
13
Period of Report
2021-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-8k_20210812.htm   iXBRL 8-K 37777
2 EX-99.1 kzr-ex991_6.htm EX-99.1 96879
  Complete submission text file 0001564590-21-043959.txt   280764

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kzr-20210812.xsd EX-101.SCH 5793
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kzr-20210812_lab.xml EX-101.LAB 20222
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kzr-20210812_pre.xml EX-101.PRE 12099
6 EXTRACTED XBRL INSTANCE DOCUMENT kzr-8k_20210812_htm.xml XML 3685
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 211167492
SIC: 2834 Pharmaceutical Preparations